成人急性白血病强化治疗67例预后分析

目的：观察成人急性白血病（ＡＬ） 患者完全缓解（ＣＲ） 后强化治疗的效果。方法：对６７ 例ＣＲ后的成人ＡＬ患者进行强化治疗，急性髓细胞性白血病（ＡＭＬ）以中剂量阿糖胞苷（ＩＤ－ Ａｒａ－ Ｃ）方案为主，急性淋巴细胞性白血病（ＡＬＬ）以中剂量氨甲蝶呤（ＩＤ－ ＭＴＸ）方案为主。结果：４８ 例ＡＭＬ患者中位ＣＲ 期１６ 个月，预期３ 年和４ 年无病生存（ＤＦＳ）为３６９％ 和２１１ ％ ；２３ 例（４７９ ％） 患者复发。１９ 例ＡＬＬ 患者中位ＣＲ 期１４ 个月，预期４ 年ＤＦＳ 为３１５％ ；１０ 例（５２６％ ） 患者复发。结论：以ＩＤ－ Ａｒａ－ Ｃ 为主的强化方案及以ＩＤ－ ＭＴＸ 为主的强化方案分别能延长ＡＭＬ及ＡＬＬ患者的ＤＦＳ，降低复发率

Analysis of 67 Cases of Adult Acute Leukemia Treated by Intensive Postremission Therapy

Objective: To observe the effects of intensified treatment in the adult acute leukemia patients after complete remission (CR) Methods: Sixty-seven cases of adult acute leukemia (AL) were studied by the postremission intensification treatment Forty-eight patients with acute myelogenous leukemia (AML) were treated by ID-Ara-C chemotherapy Nineteen patients with acute lymphoblastic leukemia (ALL) were treated by ID-MTX chemotherapy Results: The medium period of complete remission (CR) in the AML patients was 16 months The estimated disease-free survival (DFS) of 3 years and 4 years were 36 9%and 21 1%respectively Twenty-three (47 9%) patients relapsed The medium period of CR in all patients was 14 months The estimated DFS of 4 years was 31 5% Ten patients (52 6%) relapsed Conclusion: The ID-Ara-C and ID-MTX chemotherapy are effective methods in prolonging DFS in postremission patients with AML and ALL respectively